Piper Jaffray Now Rates Merck At "Hold" -- Target $60

This came out last Thursday while I was attending to other professional duties.

Some of the analysts' froth around Merck's near term growth has waned -- now that the sitagliptin franchise is slowing and prembrolizumab is being mightily pressed at roll out by BMS's nivolumab.

. . . .Target: $60

Rated: Hold. . . .

I still see Merck as a solid long term play, even at today's relatively fullsome prices. So, there you have it. Onward -- with a smile.